Melanoma clinical trial results

The NCI is sponsoring the trial under its clinical collaborative agreements with Bristol-Myers Squibb for ipilimumab and nivolumab and Cooperative Research and Development Agreements with Novartis Pharmaceuticals for dabrafenib and trametinib. View the abstract at asco. Approximately 15, physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research across three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences.

Its headquarters are in Philadelphia, Pa. Visit www. All rights reserved. Follow eaonc. Practice-Changing Trial Results for Melanoma. For further information, please visit www. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of , as amended, and Section 21E of the Securities Exchange Act of , as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events.

These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Food and Drug Administration in December The MM trial ClinicalTrials. Patients were treated with nivolumab every second week as long as there was a clinical benefit or no adverse events prohibiting further treatment.

IOIO was given from the start of administration of nivolumab and every second week for the first six weeks and thereafter, every fourth week for 41 weeks. The trial objectives were to assess safety, immune response in blood and biopsies as well as efficacy.